Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Kabasakal L., Toklu T., Yeyin N., Demirci E., Abuqbeitah M., Ocak M., ...Daha Fazla

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, cilt.26, sa.2, ss.62-68, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/mirt.08760
  • Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.62-68
  • Anahtar Kelimeler: PSMA, prostate-specific membrane antigen, Lu-177-PSMA, prostate cancer, castration-resistant prostate cancer, radionuclide therapy, SALIVARY-GLAND FUNCTION, PSMA INHIBITOR, PRECLINICAL EVALUATION, LIGAND, EXPRESSION, RADIATION, TISSUES
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617.